US S&P/Case-Shiller 20-city seasonally adjusted home price index rose 0.3% MoM in August; consensus 0.3%; prior 0.32%.

Saudi Arabia said the threat to Najran, Khamis Mushait and Abha has been lifted.

Changchun High & New Technology Industry (Group) Co., Ltd’s unit Changchun Jinsai Pharmaceutical Co., Ltd received a Drug Clinical Trial Approval Notice from the National Medical Products Administration approving a domestically manufactured drug‑registration clinical trial application for injectable GenSci136. GenSci136 is Jinsai’s self‑developed BAFF/APRIL dual‑target antagonist, classified in China as a Class 1 therapeutic biological product and intended for treatment of Sjögren’s syndrome.